Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Three Healthcare Stocks To Watch In March

|Includes:AUXL, NBIX, Repros Therapeutics Inc. (RPRX)

Health is wealth and, as the Dali Lama said, quite a number of men sacrifice their health to gain wealth, only to sacrifice the wealth in order to recuperate their health. However, for those of us that invest in healthcare stocks, it is quite clear that we need not sacrifice our health; we just need to peek in our portfolios. If you are planning on adding to your portfolio this month, you may want to consider the three emerging growth healthcare stocks mentioned in this article.

The first healthcare stock is Repros Therapeutics Inc (NASDAQ: RPRX), a $203 million market cap developer of products and services geared towards reproductive health. Repros Therapeutics is qualified to be on the list because of three remarkable events in the news. The first event is that Repros Therapeutics garnered FDA approval for its testosterone drug study. The drug, called Androxal has the potential to provide a treatment for normalizing the testosterone and luteinizing hormone levels in men. The FDA has also consented to a Type B meeting for a discussion on the Phase 3 development of Proellex. Proellex is being developed by Repros as a drug for treating uterine fibroids. And finally, the FDA has approved Repros' plan for the enrolment of more patients in the study of another drug code-named ZA-302 that is being developed. Repros holds at least three new products in its development line and investors would do well to anticipate the volume of revenue that such drugs can generate when they are finally approved.

The second healthcare stock to own in March is Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a healthcare stock with a market cap of $865 million. Auxilium Pharmaceuticals is on this list because of the strength of the financials it released in its quarterly earnings results, which saw it beating expectations by $0.11 EPS. Auxillium posted revenue of $172.50 million for the quarter over the consensus analysts' estimate of $171.20 million. Moreover, Auxillium posted a yearly revenue increase of 135.3 percent.

The third small cap on our emerging growth healthcare list is Neurocrine Biosciences, Inc. (NASDAQ: NBIX) with its $727M market cap. Neurocrine Biosciences is focused on the development of drugs for treating immune systems and nervous disorders. Based on a new report by Global Industry Analysts, the global market for CNS Therapeutics will reach some $133 billion by 2018. As a result, there is no doubt that Neurocrine may record a level of unprecedented growth in its annals sooner than you think.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.